Limit PPI Doses With New Hep C Med Epclusa

September 2016

Please see the October 2016 FDA advisory about the risk of Hepatitis B reactivation in some patients being treated for Hepatitis C.

Epclusa (ep-KLOO-suh, sofosbuvir/velpatasvir) will further simplify hepatitis C treatment.

So far, other recent hep C meds (Harvoni, Zepatier, etc) can only be used for certain hep C genotypes...and treatment duration can vary.

But Epclusa is a one-tab, once-daily med that can be used for ANY hep C genotype...and patients take just a 12-week course.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Heart Failure Remind Heart Failure Patients to Watch for Sodium in OTCs
Influenza Recommend a Quadrivalent Flu Vaccine for Kids and Adolescents
Oral Health Suggest Mixing Iron Solutions With Fruit Juice to Help Limit Teeth Staining
Testosterone Tell Men Not to Sniff After Administering Natesto Testosterone Gel
Epinephrine Suggest Veta Smart Case for Patients Who Forget to Carry Their EpiPen
Women's Health Avoid Estrogen-Containing Contraceptives in Women With Certain Conditions
Angina Recommend a Long-Acting Nitrate for Angina Based on Ease of Use and Cost
Hepatitis C Limit PPI Doses With New Hep C Med Epclusa
HIV & AIDS Feel Comfortable Recommending Either Tenofovir Form for Most HIV Patients
Practice Help Patients "Buy In" to Therapy With Motivational Interviewing
Constipation Don't Count On Docusate for Treating Constipation in Most Patients